Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

JSPR - Jasper Therapeutics, Inc.


IEX Last Trade
22.5
0.190   0.844%

Share volume: 3,026
Last Updated: Thu 26 Dec 2024 08:28:59 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%

$22.31
0.19
0.85%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-1.85%
1 Month
-4.07%
3 Months
15.23%
6 Months
3.48%
1 Year
275.87%
2 Year
291.88%
Key data
Stock price
$22.50
P/E Ratio 
0.00
DAY RANGE
$21.89 - $22.79
EPS 
$0.00
52 WEEK RANGE
$7.00 - $31.01
52 WEEK CHANGE
$202.41
MARKET CAP 
329.296 M
YIELD 
N/A
SHARES OUTSTANDING 
15.105 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.85
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$204,886
AVERAGE 30 VOLUME 
$184,249
Company detail
CEO: Ronald A. Martell
Region: US
Website: www.jaspertherapeutics.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering. The company is based in Redwood City, California.

Recent news